Importantly, however, our data demonstrate that the glycosylation of CD13 induced and expressed under tumor microenvironmental conditions, particularly in breast cancer CDX tissue, is very distinct from the glycosylation observed in endogenously CD13-expressing tissues, such as HT1080 CDX and normal tissues (liver and kidney). This evidence concerns the gene ANPEP and breast carcinoma.